Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TEV-53408 · 2 trials · 2 indications
Vh:Cd is used to assess the severity of celiac disease. It is calculated by dividing the villous height by the crypt depth. A lower ratio indicates more damage.
| Arm | Type | Description |
|---|---|---|
| TEV-53408 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TEV-53408 | DRUG | Solution for subcutaneous (sc) injection |
| Placebo | DRUG | Solution for subcutaneous (sc) injection |
Inclusion Criteria: * Diagnosis of celiac disease at least 12 months prior to screening * On a gluten-free diet for at least 12 months prior to screening * Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the trial period * Male participants (including vasectomized...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Forte Biosciences Inc. | FBRX | 1 | PHASE2 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE2 | TEV-53408 |
| Barinthus Biotherapeutics plc Sponsored ADR | BRNS | 1 | EARLY_PHASE1 | VTP-1000 |
TEV-53408 is an investigational small molecule being studied for the treatment of vitiligo and celiac disease. It is currently in clinical development, with trials evaluating its safety and efficacy in both conditions. The drug is not yet approved and remains under investigation.
TEV-53408 is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker TEVA. Teva is conducting clinical trials to evaluate the drug's safety and efficacy in vitiligo and celiac disease.
TEV-53408 is in Phase 2 clinical development for celiac disease, with an active trial assessing its efficacy and safety in adults. A separate Phase 1 trial for vitiligo is also active but not recruiting. The drug remains investigational and is not FDA approved.
TEV-53408 is being studied in two clinical trials. NCT06625177 is a Phase 1 trial testing safety and efficacy in vitiligo, enrolling 38 participants in the United States. NCT06807463 is a Phase 2 trial for celiac disease, enrolling 50 adults across the United States, Australia, and Finland.
No alternative names for TEV-53408 have been disclosed. The drug is identified solely by its code name TEV-53408 in clinical trial registrations and development communications from Teva Pharmaceutical Industries.